免疫检查点抑制剂时代的肝细胞癌肝移植:综述
本叙述性综述通过检索PubMed并手动筛选参考文献,评估免疫检查点抑制剂(ICI)在肝移植围手术期的应用。ICI可使部分不可切除肝细胞癌患者获得完全缓解和长期生存,但围移植期存在免疫介导肝损伤、感染风险增加、移植后排斥和复发等严重不良事件,因此应选择性用于特定患者而非普遍使用。
要点
- ICI可使部分不可切除肝细胞癌患者获得完全缓解并长期生存。
- ICI联合局部治疗用于降期或桥接肝移植的兴趣日益增加。
- 围移植期ICI治疗需权衡肝损伤、感染、排斥和复发风险,选择性使用。
核心结论
- ICI治疗在肝移植围手术期具有复杂性,应选择性用于特定患者而非普遍使用。
研究设计与样本
- 叙述性综述,通过检索PubMed并手动筛选参考文献,纳入评估ICI在肝移植背景下应用的相关研究。
主要发现
- ICI可使部分患者达到完全缓解并提供长期生存。
- ICI使用呈指数增长,联合局部治疗用于降期或桥接肝移植的兴趣增加。
- ICI治疗可出现客观缓解,但围移植期存在免疫介导肝损伤和感染风险增加等严重不良事件。
- 移植前降期或桥接过程中ICI与移植后排斥和复发相关。
临床怎么用
- 肝移植围手术期应选择性使用ICI,而非普遍应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ablation, surgical resection and liver transplantation (LT) are curative therapies for patients with hepatocellular carcinoma (HCC). Milan Criteria and University of California San Francisco Criteria are traditionally accepted for liver transplantation, with the expectation of favourable outcomes. In recent years, immune checkpoint inhibitors (ICI) have revolutionised the management of unresectable HCC (uHCC) and are now considered first-line systemic therapy. AIMS: In this narrative review, we aimed to comprehensively discuss the role of ICIs in the peri-transplant period, with the goal of enhancing the chances of a successful LT for advanced HCC while also decreasing the risk of recurrence post-LT. METHODS: A search of PubMed and manual screening of references was performed to identify studies evaluating ICIs in the context of LT, and relevant articles were included. RESULTS: ICIs can achieve complete response and ultimately provide long-term survival in a subset of patients. There has been an exponential increase in the use of these drugs, and increasing interest in the use of combination locoregional therapies plus ICIs as a strategy for downstaging or bridging to LT. While there can be objective responses with ICI therapy, there are potentially serious adverse events, including immune-mediated liver injury and enhanced risk of infections in the pre-LT period. Rejections and recurrence post-LT are relevant in the context of ICIs, while endeavouring to downstage or bridge HCC pre-transplant. CONCLUSIONS: ICI therapy is nuanced during the peri-transplant period and should therefore be selectively used in specific patients rather than being used ubiquitously.
引用
- Kulkarni AV, Singal AG, Reddy KR, et al. Review Article: Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors. Aliment Pharmacol Ther. 2025. PMID: 40808313. doi:10.1111/apt.70333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。